Merck KGaA in advanced talks to sell off biosims unit—and others could follow

Fierce Pharma ------ The rumors are true: When it comes to biosimilars, Merck KGaA has had enough. The German drugmaker is in advanced negotiations to sell its unit of biologic copycats, it said in its 2016 annual report. The confirmation follows an October report from Reuters that the company had brought on JPMorgan Chase & Co. to help it scout potential buyers for the business. Sources at the time said it could fetch up to $1 billion. Merck has been collaborating with Indian generics maker Dr. Reddy’s on biosimilars development since 2012, but the team has yet to bring a product to market. Its pipeline includes a copy of AbbVie’s Humira currently in phase 3 testing. To learn more click on the picture below to read the article.